A 12-Month, Multicenter, Randomized, Adaptive Design, Open-Label Study To Evaluate The Benefit Of C2-Hr Monitoring Of Neoral On Safety And Efficacy Outcomes In De Novo Cardiac Transplant Recipients Receiving Basiliximab Induction: 6-Month Results.
AMERICAN JOURNAL OF TRANSPLANTATION（2005）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要